A Phase 3 interventional study of FE 999049 and GONAL-F in Infertility, Female, sponsored by Ferring Pharmaceuticals. Completed at 11 sites in China. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-02-12.
Sponsored by Ferring Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Infertility, Female with a site in China — 18 open to participants now, 20 under way, 1 of them phase 3. Infertility, Female · China.
Among the 58 studies in Infertility, Female with a site in China, this one is the 19th largest by enrollment of the 51 interventional ones that give a count, is one of 4 that started in 2024, is one of 6 in phase 3, and was the 42nd registered.
552 studies on the registry are indexed under Infertility, Female; 135 are open to participants now.
Browse Infertility, Female studies →18 of the 58 studies in Infertility, Female with a site in China are open now. Recruiting first, the newest first:
Shanghai 6th People's Hospital · Sites in China
Ages 18–40 · Women only
Shandong University of Traditional Chinese Medicine · Sites in China
Ages 21–44 · Women only
Tang-Du Hospital · Sites in China
Ages 20–40 · Women only
Suzhou Centergene Pharmaceuticals Co.,Ltd. · Sites in China
Ages 20–40 · Women only · Healthy volunteers
Peking University Third Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 90 Infertility, Female studies recruiting now, 11 (12%) set no upper age limit and 79 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.
This study: 20 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 1 · Phase 3 6 · Phase 4 4
First in 2014; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 301 is above the median of 100 across 378 interventional studies indexed under Infertility, Female.
Median enrollment 178 across the 51 interventional studies, 2,569 across the 7 observational. Of the 19 that completed or were terminated, 3 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 58 have an industry lead sponsor. The 10 most frequent:
Ferring Pharmaceuticals is the lead sponsor of 249 studies on the registry; 4 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 14 (93%) have results posted.
Ferring Pharmaceuticals has 9 studies filed under Infertility, Female — fewer than ten, so there is no comparison to draw.
4 of the studies in Infertility, Female with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06644794Phase 3Shandong University of Traditional Chinese MedicineProgesterone-modified Natural Cycle for FET | 2027-09-10 |
| NCT06775093Peking University Third HospitalEffects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity | 2026-12-31 |
| NCT06020924Wenwen WangThe Effects of Uterine Fibroids on Pregnancy in Women | 2026-12-31 |
| NCT07409792Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical UniversityMultifaceted Benefits of Auricular Point Sticking for IVF Patients: Psychological Well-being, Sleep, and Treatment Outcomes | 2027-01-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 58 studies in Infertility, Female with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 3b clinical trial with follitropin delta (FE 999049) and Gonal-F. The trial is a randomised, controlled, assessor-blind, parallel groups, multicentre trial comparing the ovarian response of a starting dose of either 10mg or 15 mg follitropin delta to a starting dose of either 150 IU or 225 IU Gonal-F in a long GnRH agonist protocol in women undergoing an assisted reproductive technology programme in China.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The participants receive either low or high starting dose as appropriate according to Investigators Judgement. 10 or 15 µg
Drug: FE 999049
The participants receive either low or high starting dose as appropriate according to Investigators Judgement. 150 or 225 IU.
Drug: GONAL-F
FE 999049 was administered as single daily subcutaneous injections at a starting dose of either 10 or 15 µg daily that was fixed for the first five stimulation days. Based on ovarian response, the dose could be increased or decreased by 5 µg, with dose adjustments implemented not more frequently than once every 2 days per investigator's judgement. The minimum daily dose was 5 µg, and the maximum daily dose was 20 µg. Participants could be treated for a maximum of 20 days.
Also known as: Rekovelle, Follitropin Delta
GONAL-F was administered as single daily subcutaneous injections at a starting dose of either 150 or 225 IU daily that was fixed for the first five stimulation days. Based on ovarian response, the dose could be increased or decreased by 75 IU, with dose adjustments implemented not more frequently than once every 2 days per investigator's judgement. The minimum daily dose was 75 IU, and the maximum daily dose was 300 IU. Participants could be treated for a maximum of 20 days. Coasting was not allowed.
Number of Oocytes Retrieved
Time frame: On day of oocyte retrieval (up to 22 days after start of stimulation)
Number of Follicles on Stimulation Day 6 and End-of-stimulation
Time frame: Stimulation day 6 and end-of-stimulation (maximum stimulation day 20)
Serum Concentrations of Estradiol on Stimulation Day 6 and End-of-stimulation
Time frame: stimulation day 6 and end-of-stimulation (maximum stimulation day 20)
Serum Concentrations of Progesterone on Stimulation Day 6 and End-of-stimulation
Time frame: stimulation day 6 and end-of-stimulation (maximum stimulation day 20)
Number of Fertilised Oocytes
Time frame: On day 1 after oocyte retrieval (up to 23 days after start of stimulation)
Fertilisation Rate
Time frame: On day 1 after oocyte retrieval (up to 23 days after start of stimulation)
Number of Embryos (Total and Quality)
Time frame: Day 3 after oocyte retrieval
Total Gonadotropin Dose
Time frame: Up to 20 stimulation days
Number of Stimulation Days
Time frame: Up to 20 stimulation days
Positive βhCG (Positive Serum βhCG Test 13-15 Days After Transfer) Rate
Time frame: 13-15 days after transfer
Clinical Pregnancy (at Least One Gestational Sac 5-6 Weeks After Transfer) Rate
Time frame: 5-6 weeks after transfer
Vital Pregnancy (at Least One Intrauterine Gestational Sac With Fetal Heart Beat 5-6 Weeks After Transfer) Rate
Time frame: 5-6 weeks after transfer
Implantation Rate
The implantation rate was defined as the number of gestational sacs 5-6 weeks after transfer divided by number of embryos transferred.
Time frame: 5-6 weeks after transfer
Ongoing Pregnancy (at Least One Intrauterine Viable Fetus 10-11 Weeks After Transfer) Rate
Time frame: 10-11 weeks after transfer
Ongoing Implantation Rate (Number of Intrauterine Viable Fetuses 10-11 Weeks After Transfer Divided by Number of Embryos Transferred)
The ongoing implantation rate was defined as the number of intrauterine viable fetuses 10-11 weeks after transfer divided by the number of embryos transferred.
Time frame: 10-11 weeks after transfer
Early Ovarian Hyperstimulation Syndrome (OHSS), Late OHSS, and Total OHSS (All Overall and by Grade)
Early OHSS was defined as OHSS with onset ≤9 days after triggering of final follicular maturation. Late OHSS was defined as OHSS with onset \>9 days after triggering of final follicular maturation. Total OHSS measure the incidence of OHSS both early and late.
Time frame: ≤9 days after triggering of final follicular maturation (early OHSS), >9 days after triggering of final follicular maturation until 21-28 days after last IMP dose or up to ongoing pregnancy 8-9 weeks after transfer in pregnant participants (late OHSS)
| Milestone | FE 999049 | GONAL-F |
|---|---|---|
| Started | 148 | 153 |
| Completed | 126 | 131 |
| Not completed | 22 | 22 |
| Oocytes retrieved | FE 999049 | GONAL-F |
|---|---|---|
| Number of Oocytes Retrieved | 12.7 ± 5.2 | 11.8 ± 5.3 |
| Follicles | FE 999049 | GONAL-F |
|---|---|---|
| Stimulation day 6 | 2.9 ± 3.0 | 3.0 ± 3.3 |
| End of stimulation | 13.3 ± 4.4 | 12.7 ± 4.5 |
| pmol/L | FE 999049 | GONAL-F |
|---|---|---|
| Stimulation day 6 | 1303.2 ± 1093.1 | 1275.9 ± 1050.8 |
| End of stimulation | 11181.2 ± 5842.2 | 10124.1 ± 4522.2 |
| nmol/L | FE 999049 | GONAL-F |
|---|---|---|
| Stimulation day 6 | 1.6 ± 0.9 | 1.4 ± 0.8 |
| End of Stimulation | 3.4 ± 1.6 | 2.8 ± 1.3 |
| Fertilised Oocytes | FE 999049 | GONAL-F |
|---|---|---|
| Number of Fertilised Oocytes | 7.8 ± 4.3 | 7.4 ± 4.3 |
| percentage of fertilised oocytes | FE 999049 | GONAL-F |
|---|---|---|
| Fertilisation Rate | 59.6 ± 19.9 | 62.7 ± 20.9 |
| Embryos | FE 999049 | GONAL-F |
|---|---|---|
| Total | 8.8 ± 4.6 | 8.2 ± 4.6 |
| Good-Quality | 5.5 ± 3.7 | 5.1 ± 3.7 |
| ug | FE 999049 | GONAL-F |
|---|---|---|
| Total Gonadotropin Dose | 154.1 ± 41.0 | 167.7 ± 48.4 |
| days | FE 999049 | GONAL-F |
|---|---|---|
| Number of Stimulation Days | 10.6 ± 1.5 | 10.5 ± 1.7 |
| Participants | FE 999049 | GONAL-F |
|---|---|---|
| Positive | 71 | 72 |
| Negative | 77 | 81 |
| Participants | FE 999049 | GONAL-F |
|---|---|---|
| Positive | 61 | 56 |
| Negative | 87 | 97 |
| Participants | FE 999049 | GONAL-F |
|---|---|---|
| Positive | 59 | 50 |
| Negative | 89 | 103 |
The implantation rate was defined as the number of gestational sacs 5-6 weeks after transfer divided by number of embryos transferred.
| percentage of embryos transferred | FE 999049 | GONAL-F |
|---|---|---|
| Implantation Rate | 40.5 | 62 |
| Participants | FE 999049 | GONAL-F |
|---|---|---|
| Positive | 54 | 45 |
| Negative | 94 | 108 |
The ongoing implantation rate was defined as the number of intrauterine viable fetuses 10-11 weeks after transfer divided by the number of embryos transferred.
| percentage of embryos transferred | FE 999049 | GONAL-F |
|---|---|---|
| Ongoing Implantation Rate (Number of Intrauterine Viable Fetuses 10-11 Weeks After Transfer Divided by Number of Embryos Transferred) | 36.2 | 26.2 |
Early OHSS was defined as OHSS with onset ≤9 days after triggering of final follicular maturation. Late OHSS was defined as OHSS with onset \>9 days after triggering of final follicular maturation. Total OHSS measure the incidence of OHSS both early and late.
| Participants | FE 999049 | GONAL-F |
|---|---|---|
| Early OHSS | 4 | 8 |
| Late OHSS | 2 | 1 |
| Total OHSS | 6 | 9 |
Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FE 999049 | 0/148 (0%) | 4/148 (2.7%) | 16/148 (10.8%) |
| GONAL-F | 0/153 (0%) | 11/153 (7.2%) | 25/153 (16.3%) |
| Event | FE 999049 | GONAL-F |
|---|---|---|
| Abortion SpontaneousPregnancy, puerperium and perinatal conditions | 1/148 | 4/153 |
| Abortion ThreatenedPregnancy, puerperium and perinatal conditions | 1/148 | 3/153 |
| Ectopic PregnancyPregnancy, puerperium and perinatal conditions | 0/148 | 3/153 |
| Ovarian Hyperstimulation SyndromeReproductive system and breast disorders | 1/148 | 2/153 |
| Dengue FeverInfections and infestations | 1/148 | 0/153 |
| Bartholin's abscessInfections and infestations | 0/148 | 1/153 |
| Event | FE 999049 | GONAL-F |
|---|---|---|
| Biochemical PregnancyPregnancy, puerperium and perinatal conditions | 8/148 | 15/153 |
| Morning SicknessPregnancy, puerperium and perinatal conditions | 12/148 | 10/153 |
| Upper respiratory tract infectionInfections and infestations | 9/148 | 5/153 |
| HydrometraReproductive system and breast disorders | 9/148 | 7/153 |
| Abortion SpontaneousPregnancy, puerperium and perinatal conditions | 8/148 | 5/153 |
| Pelvic discomfortReproductive system and breast disorders | 8/148 | 8/153 |
| Age, Continuous(Years) | FE 999049 | GONAL-F | Total |
|---|---|---|---|
| Mean | 32.5 ± 3.6 | 32.2 ± 3.8 | 32.3 ± 3.7 |
| Sex: Female, Male(Participants) | FE 999049 | GONAL-F | Total |
|---|---|---|---|
| Female | 148 | 153 | 301 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | FE 999049 | GONAL-F | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 148 | 153 | 301 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | FE 999049 | GONAL-F | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 148 | 153 | 301 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | FE 999049 | GONAL-F | Total |
|---|---|---|---|
| China | 148 | 153 | 301 |
| Dose Group(Participants) | FE 999049 | GONAL-F | Total |
|---|---|---|---|
| Low Starting Dose | 47 | 51 | 98 |
| High Starting Dose | 101 | 102 | 203 |
| Body Measurement (Weight)(kg) | FE 999049 | GONAL-F | Total |
|---|---|---|---|
| Mean | 57.5 ± 8.3 | 57.5 ± 7.7 | 57.5 ± 8.0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2024 to primary completion in May 2025, 14 months.
Results were first posted in Feb 2026, 8 months after primary completion.
Of 28 phase 3 interventional studies under Infertility, Female, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 42. This study's 14 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Follitropin delta